ESTRO meets Asia 2024 - Abstract Book
S275
Interdisciplinary – Upper GI
ESTRO meets Asia 2024
A systematic literature search was conducted in PubMed, EMBASE, and CENTRAL databases. Key eligibility criteria included studies that enrolled patients with histologically confirmed EC or esophagogastric junction cancer (EGJC) with metastasis or recurrence and compared survival benefits between the combined local and systemic treatment group and the systemic treatment alone group. Survival outcomes, represented by hazard ratios (HRs) of progression-free survival (PFS) and overall survival (OS), were pooled using a random-effect model. The MINORS score was adopted for quality assessment. Risk of bias was statistically examined by Begg's and Egger's tests.
Results:
A total of 1 randomized controlled trial (RCT) and 10 qualified retrospective studies including 14489 patients were identified. Addition of local therapy to systemic treatment significantly improved PFS (HR 0.52, 95% CI 0.37–0.73, p < 0.001) and OS (HR 0.69, 95% CI 0.58–0.81, p < 0.0001) compared with systemic treatment alone. The subgroup analysis revealed that combined local and systemic treatment had significant survival advantage in both patients with oligometastatic (PFS: HR 0.45, 95% CI 0.31–0.64, p < 0.0001); OS: HR 0.62, 95% CI 0.48–0.79, p < 0.0001) and recurrence (OS: HR 0.55, 95% CI 0.37–0.81, p = 0.002).
Conclusion:
In conclusion, addition of local treatment to systemic therapy can improve survival in patients with advanced esophageal cancer, particularly in those with oligometastatic or recurrent diseases.
Keywords: advanced EC, local therapy, meta-analysis
References:
[1] Liu, Q.; Chen, J.; Lin, Y.; Ye, J.; Shen, W.; Luo, H.; Li, B.; Huang, W.; Wei, S.; Song, J.; Wang, Y.; Yang, H.; Lai, S.; Zhu, H.; Ai, D.; Chen, Y.; Deng, J.; Hao, S.; Zhao, K., Systemic therapy with or without local intervention for oligometastati c oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label , randomised, phase 2 trial. The lancet. Gastroenterology & hepatology 2023, S2468-1253(23)00316-3. [2] Wu, X.; Li, Y.; Zhang, K.; Guo, Z.; Li, Y.; Zhao, F.; Zhang, T.; Chen, X.; Wei, H.; Zhang, W.; Wang, P.; Pang, Q., Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study. Clinical and translational radiation oncology 2022, 38, 130-137. [3] Shi, Z.; Zhu, X.; Ruan, C.; Wei, G.; Li, J.; Qiu, H.; Gao, L.; Cai, G.; Zhangcai, Y.; Li, B.; Wang, J.; Gong, Y.; Chen, J.; Zhao, W.; Wu, Y.; Ke, S.; Chen, Y., Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients with Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma. JAMA Network Open 2022, 5 (12), E2244619. [4] Kroese, T. E.; Buijs, G. S.; Burger, M. D. L.; Ruurda, J. P.; Mook, S.; Brosens, L. A. A.; van Rossum, P. S. N.; van Hillegersberg, R., Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer. Annals of Surgical Oncology 2022, 29 (8), 4848-4857. [5] Shao, Y.; Zhang, M.; Ye, L.; Chen, D.; Wu, Q. C.; Zhang, C., Survival differences between chemotherapy and chemoradiotherapy in metastatic esophageal cancer: a propensity score-matched study based on the SEER database. Annals of palliative medicine 2021, 10 (4), 3826-3835.
Made with FlippingBook flipbook maker